Human cTnT/TNNT2 (Troponin T Type 2, Cardiac) CLIA Kit
The Human CTnT (Troponin T Type 2) Cardiac CLIA Kit is a cutting-edge assay designed for the precise measurement of CTnT levels in human serum samples. This kit offers unparalleled sensitivity and accuracy, guaranteeing consistent and trustworthy results for a variety of research purposes.CTnT is a critical biomarker for assessing cardiac health, particularly in the diagnosis and monitoring of acute coronary syndromes and other heart-related conditions.
Its measurement can provide valuable insights into cardiac muscle damage, helping to guide treatment decisions and improve patient outcomes.With its advanced technology and reliable performance, the Human CTnT Cardiac CLIA Kit is an indispensable tool for researchers and clinicians alike who are focused on understanding and managing cardiac diseases. Trust in this kit to deliver the precise data you need for your cardiovascular research efforts.
Product Name:
Human cTnT/TNNT2 (Troponin T Type 2, Cardiac) CLIA Kit
SKU:
HUES00427
Target:
Human cTnT/TNNT2 (Troponin T Type 2, Cardiac)
Size:
96T
Assay type:
Sandwich-CLIA
Assay time:
3.5h
Sensitivity:
7.50 pg/mL
Detection range:
12.50-800 pg/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
CLIA Plate
8 wells x 3 strips
8 wells x 12 strips
-20°C, 6 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 6 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 6 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent A
1 vial, 5 mL
1 vial, 5 mL
4°C (shading light)
Substrate Reagent B
1 vial, 5 mL
1 vial, 5 mL
Desiccant
1
1
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human cTnT/TNNT2. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human cTnT/TNNT2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human cTnT/TNNT2, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human cTnT/TNNT2. You can calculate the concentration of Human cTnT/TNNT2 in the samples by comparing the RLU value of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
94-108
94-109
86-102
Average (%)
102
100
93
1:4
Range (%)
100-114
101-117
88-100
Average (%)
107
110
94
1:8
Range (%)
98-111
102-117
88-99
Average (%)
105
109
94
1:16
Range (%)
93-107
91-104
93-108
Average (%)
99
98
100
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
92-106
98
EDTA plasma (n=5)
84-100
91
Cell culture media (n=5)
90-103
97
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20.0
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
36.74
99.9
373.92
38.61
97.45
402.45
Standard deviation
3.61
8.61
32.46
4.98
6.97
32.48
C V (%)
9.83
8.62
8.68
12.9
7.15
8.07
Sample type &Sample volume:
serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 15%.
Application:
This CLIA kit applies to the in vitro quantitative determination of Human cTnT/TNNT2 concentrations in serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human cTnT/TNNT2 in samples. No significant cross-reactivity or interference between Human cTnT/TNNT2 and analogues was observed.
